Plain-English translation of NCT05877430 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new treatment called combined with a well-known immunotherapy drug called pembrolizumab in people with advanced cancers that have spread or cannot be surgically removed. The trial aims to understand whether adding this medication to pembrolizumab can help people whose cancers haven't responded well to immunotherapy alone, or who are starting treatment for the first time.
Many people with advanced lung, head and neck, or skin cancers don't respond well to immunotherapy treatments. This trial is designed to see if the new treatment can work better when combined with existing immunotherapy to help more patients benefit.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as a capsule you take by mouth, combined with pembrolizumab given as an intravenous infusion. The trial has two phases: in Phase 1, researchers test different dose levels to find the safest and most effective dose; in Phase 2, participants receive the dose chosen from Phase 1. Throughout the study, you will have regular visits to check how well the treatment is working, monitor for side effects, and provide tissue samples to help researchers understand how the treatment affects your immune system and gut bacteria.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
South Korea